Michael U. Callaghan
Agios Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Hemophilia Treatment and Research, Hemoglobinopathies and Related Disorders, Platelet Disorders and Treatments, Iron Metabolism and Disorders, Blood Coagulation and Thrombosis Mechanisms
Most-Cited Works
- → Emicizumab Prophylaxis in Hemophilia A with Inhibitors(2017)1,046 cited
- → Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors(2018)717 cited
- → UPR Pathways Combine to Prevent Hepatic Steatosis Caused by ER Stress-Mediated Suppression of Transcriptional Master Regulators(2008)583 cited
- → Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia(2015)324 cited
- → Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies(2020)275 cited
- → Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A(2022)98 cited
- → The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study(2018)94 cited
- → Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study(2020)94 cited
- → Genotype-phenotype correlation in combined deficiency of factor V and factor VIII(2008)81 cited
- → Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection(2021)78 cited